52 research outputs found
The AMMA mulid network for aerosol characterization in West Africa
Three ground based portable low power consumption microlidars (MULID) have
been built and deployed at three remote sites in Banizoumbou (Niger), Cinzana
(Mali) and M'Bour (Senegal) in the framework of the African Monsoon
Multidisciplinary Analyses (AMMA) project for the characterization of aerosols
optical properties. A description of the instrument and a discussion of the
data inversion method, including a careful analysis of measurement
uncertainties (systematic and statistical errors) are presented. Some case
studies of typical lidar profiles observed over the Banizoumbou site during
2006 are shown and discussed with respect to the AERONET 7-day
back-trajectories and the biomass burning emissions from the Combustion
Emission database for the AMMA campaign
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer
Objectives: To characterize the safety, tolerability, and anti-tumor activity of cemiplimab as monotherapy or in combination with hypofractionated radiation therapy (hfRT) in patients with recurrent or metastatic cervical cancer. To determine the association between histology and programmed death-ligand 1 (PD-L1) expression.
Methods: In non-randomized phase I expansion cohorts, patients (squamous or non-squamous histology) received cemiplimab 3 mg/kg intravenously every 2 weeks for 48 weeks, either alone (monotherapy cohort) or with hfRT during week 2 (combination cohort). Due to insufficient tissue material, PD-L1 protein expression was evaluated in commercially purchased samples and mRNA expression levels were analyzed from The Cancer Genome Atlas (TCGA).
Results: Twenty patients enrolled in both cohorts in total; 10 had squamous histology. The most common adverse events of any grade were diarrhea, fatigue, and hypokalemia, occurring in 35%, 25%, and 25%, respectively. Objective response rate was 10% in each cohort; responders had squamous histology. Duration of response was 11.2 months and 6.4 months for the responder in the monotherapy and combination cohort, respectively. Irradiated lesions were not included in the response assessments. In separate archived specimens (N = 155), PD-L1 protein expression in tumor and immune cells was negative (<1%) more commonly in adenocarcinoma than in squamous tumors. PD-L1 mRNA levels were lower in adenocarcinoma than squamous cell tumors (1.2 vs 5.0 mean transcripts per million, respectively) in TCGA.
Conclusions: Cemiplimab has activity in cervical squamous cell carcinoma. The phase I results, combined with results from other anti-PD-1 trials in cervical cancer and our biomarker analyses have informed the design of the ongoing phase III trial, with the primary overall survival hierarchical analyses being done first in patients with squamous histology
Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference.
Focal radiation therapy (RT) has attracted considerable attention as a combinatorial partner for immunotherapy (IT), largely reflecting a well-defined, predictable safety profile and at least some potential for immunostimulation. However, only a few RT-IT combinations have been tested successfully in patients with cancer, highlighting the urgent need for an improved understanding of the interaction between RT and IT in both preclinical and clinical scenarios. Every year since 2016, ImmunoRad gathers experts working at the interface between RT and IT to provide a forum for education and discussion, with the ultimate goal of fostering progress in the field at both preclinical and clinical levels. Here, we summarize the key concepts and findings presented at the Sixth Annual ImmunoRad conference
Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.
Cells succumbing to stress via regulated cell death (RCD) can initiate an adaptive immune response associated with immunological memory, provided they display sufficient antigenicity and adjuvanticity. Moreover, multiple intracellular and microenvironmental features determine the propensity of RCD to drive adaptive immunity. Here, we provide an updated operational definition of immunogenic cell death (ICD), discuss the key factors that dictate the ability of dying cells to drive an adaptive immune response, summarize experimental assays that are currently available for the assessment of ICD in vitro and in vivo, and formulate guidelines for their interpretation
Transverse momentum spectra of charged particles in proton-proton collisions at GeV with ALICE at the LHC
The inclusive charged particle transverse momentum distribution is measured
in proton-proton collisions at GeV at the LHC using the ALICE
detector. The measurement is performed in the central pseudorapidity region
over the transverse momentum range GeV/.
The correlation between transverse momentum and particle multiplicity is also
studied. Results are presented for inelastic (INEL) and non-single-diffractive
(NSD) events. The average transverse momentum for is (stat.) (syst.) GeV/ and
\left_{\rm NSD}=0.489\pm0.001 (stat.) (syst.)
GeV/, respectively. The data exhibit a slightly larger than measurements in wider pseudorapidity intervals. The results are
compared to simulations with the Monte Carlo event generators PYTHIA and
PHOJET.Comment: 20 pages, 8 figures, 2 tables, published version, figures at
http://aliceinfo.cern.ch/ArtSubmission/node/390
Local approaches to hereditary breast cancer
The diagnostic and local treatment modalities of hereditary breast cancer (HBC) are evolving based on emerging evidence from new imaging, radiotherapy and surgical studies. The optimal selection of diagnostic and therapeutic strategies for the individual HBC patient remains an area of active research in this relatively new patient population. In this context, some rational pathways of intervention are currently available to both reduce cancer risk in mutation carriers without a cancer diagnosis, as well as to reduce the risk of recurrence or new cancers among the carriers already diagnosed with a malignancy. It is encouraging to notice to what degree certain interventions have successfully reduced both the risk of malignancy and the anxiety associated with this genetic diagnosis. This updated report aims at summarizing the most recent findings, while it identifies the areas of uncertainty that remain, and continue to present difficult challenges, particularly among younger HBC patients
The International Cancer Expert Corps (ICEC): Implementing a global force to address the catastrophic rise in cancer in the developing world.
- …